Quality assurance in radiotherapy

European Journal of Cancer

Volumn 39, Issue 4, 2003, Pages 415-422

  Kouloulias, V E ^a  

^a Cancer Data Center   (Belgium)

Author keywords

EORTC; Quality assurance; Radiotherapy

Indexed keywords

FLUOROURACIL; FOLINIC ACID; GONADORELIN DERIVATIVE;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONSERVATIVE TREATMENT; HUMAN; ONCOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY CONTROL; RADIATION DOSE DISTRIBUTION; RECTUM CANCER; REVIEW; THERMOLUMINESCENCE DOSIMETRY; TREATMENT PLANNING;

EID: 0037365065     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(02)00461-6     Document Type: Article

References (46)

1. Horiot J.C., Johansson K.A., Gonzalez D.G., van der Schueren E., van den Bogaert W., Notter G. Quality assurance control in the EORTC cooperative group of radiotherapy. 1. Assessment of radiotherapy staff and equipment. European Organisation for Research and Treatment of Cancer. Radiother. Oncol. 6:1986;275-284.
2. Johansson K.A., Horiot J.C., Van Dam J., Lepinoy D., Sentenac I., Sernbo G. Quality assurance control in the EORTC cooperative group of radiotherapy. 2. Dosimetric intercomparison. Radiother. Oncol. 7:1986;269-279.
3. Johansson K.A., Horiot J.C., van der Schueren E. Quality assurance control in the EORTC cooperative group of radiotherapy. 3. Intercomparison in an anatomical phantom. Radiother. Oncol. 9:1987;289-298.
4. Van Dam J., Johansson K.A., Bridier A., Sernbo G., Hansson U. EORTC radiotherapy group quality assurance. mechanical checks and beam alignments of megavoltage equipment Radiother. Oncol. 29:1993;91-96.
5. Hansson U., Johansson K.A., Horiot J.C., Bernier J. Mailed TL dosimetry programme for machine output check and clinical in the application in the EORTC radiotherapy group. Radiother. Oncol. 29:1993;85-90.
6. Horiot J.C., Bernier J., Johansson K.A., van der Schueren E., Bartelink H. Minimum requirements for quality assurance in radiotherapy. Radiother. Oncol. 29:1993;103-104.
7. Derreumaux S., Chavaudra J., Bridier A., Rossetti V., Dutreix A. European quality assurance network for radiotherapy. dose measurement procedure Phys. Med. Biol. 40:1995;1191-1208.
8. Bernier J., Horiot J.C., Bartelink H.et al. Profile of radiotherapy departments contributing to the Cooperative Group of Radiotherapy of the European Organisation for Research and Treatment of Cancer. Int. J. Radiat. Oncol. Biol. Phys. 34:1996;953-960.
9. Bentzen S.M., Bernier J., Davis J.B.et al. Clinical impact of dosimetry quality assurance programmes assessed by radiobiological modeling of data from the thermoluminescent dosimetry study of the European Organisation for Research and Treatment of Cancer. Eur. J. Cancer. 36:2000;615-620.
10. Johansson K.A., Hanson W.F., Horiot J.C. Workshop of the EORTC Radiotherapy Group on quality assurance in cooperative trials of radiotherapy. a recommendation for EORTC Cooperative Groups Radiother. Oncol. 11:1988;201-203.
11. Horiot J.C. Rationale for a quality assurance programme in clinical trials of conservative management of breast carcinoma. European Organisation for the Research and Treatment of Cancer. Radiother. Oncol. 22:1991;222-225.
12. Bartelink H., Garavaglia G., Johansson K.A.et al. Quality assurance in conservative treatment of early breast cancer. Report on a consensus meeting of the EORTC Radiotherapy and Breast Cancer Cooperative Groups and the EUSOMA (European Society of Mastology). Radiother. Oncol. 22:1991;323-326.
13. Bartelink H., Bernier J., Kurtz J., Garavaglia G. Radiother. Oncol. 29:1993;xi-xii.
14. Horiot J.C., van der Schueren E., Johansson K.A., Bernier J., Bartelink H. The programme of quality assurance of the EORTC radiotherapy group. A historical review. Radiother. Oncol. 29:1993;81-84.
15. Pavy J.J., Denekamp J., Letschert J.et al. EORTC Late Effects Working Group. Late effects toxicity scoring: the SOMA scale. Radiother. Oncol. 35:1995;11-15.
16. Bolla M., Bartelink H., Garavaglia G.et al. EORTC guidelines for writing protocols for clinical trials of radiotherapy. Radiother. Oncol. 36:1995;1-8.
17. van Tienhoven G., van Bree N.A., Mijnheer B.J., Bartelink H. Quality assurance of the EORTC trial 22881/10882. "assessment of the role of the booster dose in breast conserving therapy": the Dummy Run. EORTC Radiotherapy Cooperative Group Radiother. Oncol. 22:1991;290-298.
18. van Tienhoven G., Mijnheer B.J., Bartelink H., Gonzalez D.G. Quality assurance of the EORTC Trial 22881/10882. boost versus no boost in breast conserving therapy. An overview Strahlenther. Onkol. 173:1997;201-207.
19. Dusserre A., Garavaglia G., Giraud J.Y., Bolla M. Quality assurance of the EORTC radiotherapy trial 22863 for prostatic cancer. the dummy run Radiother. Oncol. 36:1995;229-234.
20. Valley J.F., Bernier J., Tercier P.A.et al. Quality assurance of the EORTC radiotherapy trial 22931 for head and neck carcinomas. the dummy run Radiother. Oncol. 47:1998;37-44.
21. Meunier F., Horiot J.C. EORTC scientific strategy meeting 25-26 March. Eur. J. Cancer. 1999:1999;35. 1423-1430.
22. Poortmans P.M., Venselaar J.L., Struikmans H.et al. The potential impact of treatment variations on the results of radiotherapy of the internal mammary lymph node chain. a quality-assurance report on the dummy run of EORTC Phase III randomised trial 22922/10925 in stages I-III breast cancer(1) Int. J. Radiat. Oncol. Biol. Phys. 49:2001;1399-1408.
23. Bosset J.F., Magnin V., Maingon P.et al. Preoperative radiochemotherapy in rectal cancer. long-term results of a phase II trial Int. J. Radiat. Oncol. Biol. Phys. 46:2000;323-327.
24. Bosset J.F., Pelissier E.P., Mantion G., Horiot J.C., Pavy J.J. Concomitant preoperative radiochemotherapy for rectal cancers. Ann. Chir. 50:1996;302-310.
25. Bosset JF. Four arms phase III clinical trial for T3-T4 resectable rectal cancer comparing pre-operative pelvic irradiation to pre-operative irradiation combined with fluoroucil and leucovorin with or without post-operative adjuvant chemotherapy. Protocol 22921. EORTC Radiotherapy Cooperative Group.
26. Bosset J.F., Maingon P. Adjuvant chemoradiotherapy of cancers of the rectum. Cancer Radiother. 2:1998;703-707.
27. Bolla M, de Reijke T. Long term adjuvant hormonal treatment with LHRH analogue versus no further treatment in locally advanced prostatic carcinoma treated by external irradiation and six months combined androgen blockage - a phase III study. EORTC Trial 22961. A joint trial of the EORTC Radiotherapy and EORTC Genito-Urinary Tract Cancer Cooperative Group. EORTC DATA CENTER, Brussels, 1997.
28. Bolla M. EORTC Radiotherapy Cooperative Group, three dimensional conformal radiotherapy alone vs three dimensional conformal therapy plus adjuvant hormonal therapy in localized T1b-c, T2a, N0, M0 prostatic carcinoma. A Phase III Randomized Study. EORTC PROTOCOL 22991. Brussels, 2000.
29. Van den Bogaert W, Struikmans H, Fourquet A, Bartelink H. Internal mammary and medial supraclavicular (IM-MS) lymph node chain irradiation in stages I-III breast cancer. A phase III randomised trial of the EORTC, protocol 22922/10925, May 1996, revision May 1999.
30. Fowble B., Hanlon A., Freedman G.et al. Internal mammary node irradiation neither decreases distant metastases nor improves survival in stage I and II breast cancer. Int. J. Radiat. Oncol. Biol. Phys. 47:2000;883-894.
31. Edland R.B. Presidential address. does adjuvant radiotherapy have a role in the postmastectomy management of patients with operable breast cancer - revisited Int. J. Radiat. Onc. Biol. Phys. 15:1988;519-535.
32. Fletcher G.H., Montague E.D. Does adequate irradiation of the internal mammary chain and supraclavicular nodes improve survival rates? Int. J. Radiat. Onc. Biol. Phys. 4:1978;481-492.
33. Kaija H., Mauna P. Tangential breast irradiation with or without internal mammary chain irradiation. results of a randomized trial Radiother. Oncol. 36:1995;172-176.
34. Nath R., Biggs P.J., Bova F.J.et al. American Association of Physicists in Medicine (AAPM) code of practice for radiotherapy accelerators. Report of AAPM Radiation Therapy Task Group No 45 Med. Phys. 21:1994;1093-1121.
35. Brahme A., Chavaudra J., Landberg T.et al. Accuracy requirements and quality assurance of external beam therapy with photons and electrons. Acta Oncol. (Stockholm) Suppl. 1:1988;1-76.
36. Institute of Physical Sciences in Medicine (IPSM). Report No. 54. Commissioning and quality assurance of linear accelerators. IPSM Publications, York, United Kingdom, 1988.
37. International Electrotechnical Commission (IEC). Technical Report 977. Medical electrical equipment. Medical electron accelerators in the range 1 MeV to 50 MeV - guidelines for functional performance characteristics. IEC, Geneva, Switzerland, 1989.
38. Johansson K.A., Sernbo G., Van Dam J. Quality Control of Megavoltage Therapy Units, Radiotherapy Physics in Practice. 1993;Oxford university press, Oxford, UK. p. 77-94.
39. Netherlands Commission on Radiation Dosimetry (NCS). Quality control of medical linear accelerators. Current practice and requirements. Report No.9, August 1996.
40. Part 5: Medizinische Elektronenbeschleuniger-Anlangen; Konstanz-prufungen von Kennmerkmalen. 1997;Beuth-Verlag, Berlin.
41. Publication 4. Quality Control of Electron Accelerators for Medical Use. SFPH. 1989;Institut Curie, Paris, France.
42. Quality Assurance in radiotherapy. 1988;WHO, Geneva.
43. European Commission. Radiation protection 102 (Environment, Nuclear Safety and Civil Protection). Implementation of the "Medical Exposure Directive" (97/43/Euratom) Proceedings of the international workshop held in Madrid on 27 April 1998. Acceptability criteria for radiological installations and quality assurance programmes. 1998, pp. 27-42.
44. Michalski JM, Purdy JA, Harms W and Matthews JW. The CT-Simulation 3-D Treatment Planning Process, Frontiers of Radiation Therapy and Oncology, Vol. 29. Basel, Karger, 1996, pp. 43-56.
45. Telematics Applications Programme Project Virtuoso (Virtual Simulation and Treatment via Telematics Applications in Clinical Radio-oncology), CEC DG IX, 1998-2000.
46. Olsen D., Bruland O.S., Davis B. Telemedicine in radiotherapy treatment planning. requirements and applications Radiother. Oncol. 54:2000;255-259.